Professional Documents
Culture Documents
Gastrointestinal Problems
Badriul Hegar
Department of Pediatric, University of Indonesia
GASTROINTESTINAL
TRACT
100.000 billion bacteria
80% of all antibody producing
cells
barrier between in- and out-side world
GALT
Gut Associated Lymphoid Tissue
The immune system of gastrointestinal tract
The largest mass of lymphoid tissue in the
human body
important element of the total immunologic
capacity
Microorganisms and food are necessary
for development of GALT
Ruthlein. 1992
Ps-Aeruginosa
Production of toxin;
diarrhea, constipation;
Infection; liver
demage;cancer;
encephalopathy
Proteus
Inhibition of growth of
exogenous and/or
harmful bacteria
Staphylococci
Clostridia
Veillonellae
Production
of carcinogenic
Stimulation of immune
function
Enterococci
E. coli
Lactobacilli
Intestinal putrefaction
Streptococci
Eubacteria
Bifidobacteria
Bacteroides
Synthesis of vitamins
Probiotic Concept
FAO/WHO recommended definition:
Probiotics: Live microorganisms which when
administered in adequate amounts confer a
health benefit on the host
Importance of Probiotics
Competitive
binding
on intestinal
mucosa
Lowering
pH in environment
Synthesis of
vitamins, enzymes
Mechanical defence
skin,
skin, mucosa, mucus layer
Immunological defence
antibodies,
antibodies, cytokines,
cytokines,
WBC,
WBC, macrophages
Biological defence
micro
micro flora
flora
Chemical defence
SCFA,
SCFA, acidic
acidic pH
pH
Infectious
diarrhea
Probiotics for treating infectious
diarrhea
Effects of probiotics in proven or presumed
23 studies met inclusion
criteria (randomised, blind)
infectious
diarrhea
1917 participants/countries with low overall mortality rates
varied in
probiotic(s) tested
dosage, methodological quality
diarrhea definitions, outcome
Infectious
diarrhea
56
114.7 + 16.2
p
122.9 + 33.0
45
136.3 + 29.0
26
120.8 + 44.1
risk
LGG
Placebo
prevalence rota-pos
20
27.8%
risk ROTA-Gastroenteritis
relative risk 0.13 (95% CI 0.02 - 0.79)
2.2
17%
ang JS.
uang
JS. Dig
Dig Dis
Dis Sci
Sci 2002;47:2625-34
2002;47:2625-34
Abstract
a prospective randomized, multicenter single blinded clinical trial in
hospitalized children with acute watery diarrhea.
Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium
bifidum, Bifidobacterium longum, Enterococcus faecium, and 625
mg fructooligosaccharide) for 5 days
Result
The duration of diarrhea was significantly shorter (36 h) in
children receiving the synbiotic group than the controls (77.930.5
vs. 114.6 37.4 h, p<0.0001).
The duration of hospitalization was shorter in children
receiving the synbiotic group (4.941.7 vs. 5.771.97 days,
p00.002).
Treatment of Acute
Diarrhea
Probiotics reduce diarrhea duration and
frequency
Dose-dependent with 1010 CFU/day effective
Pediatr 2002;109:678-684 (meta-analysis)
Probiotics in Prevention of
Antibiotic Associated Diarrhea
AAD : rate : 5 to 39 %
uncomplicated diarrhoea <--> severe colitis
(pseudomembranes)
pathogenesis:
disruption of normal flora
overgrowth pathogens
metabolic imbalances
Conclusions
The pooled evidence suggests that probiotics
are associated with a reduction in AAD.
More research is needed to determine which probiotics are
associated with the greatest efficacy and for which patients
receiving which specific antibiotics.
Prevention of antibiotic-associated
diarrhea
in children
RR (95%CI)
0.3 [0.09, 1.1]
0.3 [0.13, 0.6]
Lactobacillus GG
Arvola (n=119)
Vanderhoof (n=188)
L. acidophilus/B. infantis
Jirapinyo (n=18)
L. acidophilus/L. bulgaricus
Tankanow (n=38)
B. lactis/Str. thermophilus
Correa (n=80)
Probiotics in IBS in
children
RCT, N=50, age 6-20 years, IBS (Rome criteria)
Intervention : LGG or placebo, 6 weeks
Gastrointestinal Symptom Rating Scale
Response rate
44% vs. 40%, p=0.8
Lower incidence of perceived abdominal
distention in LGG group
Bausserman J Pediatr 2005;147:197-201
UC
Colon
Pouchitis
Ileal pouch
Mucosal adherence
Mucosal invasion
Colon
+
+
?
Relapse
LGG 31% vs. placebo
17%
RR 1.9 (0.8 to 4.4)
Time to relpase
- 9.8 vs. 11 months
(p=0.24)
Bousvaros et al. Inflamm Bowel Dis 2005;11:833-9
Megraud F. Curr Infect Dis Rep. 2005 Mar;7(2):115-120; Aliment Pharmacol Ther 2002;16:1669-1675
patients randomized in 4
groups
probiotic or placebo both during and for 7 days after
a 1-wk triple therapy scheme
omeprazole 20 mg b.id
clarithromycin 500 mg b.i.d.
tinidazole 500 mg b.i.d.
Group
Group
Group
Group
I
II
III
IV
(n = 21)
(n = 22)
(n = 21)
(n = 21)
Lactobacillus GG
Saccharomyces boulardii
Lactobacillus spp. and bifidobacteria
placebo
Placebo
Hard Stool
Soft Stool
Loose Stool
3.3
High suppl
37.8 ()
Low suppl
29.4 (#)
56.7
3.0
42.5
Constipation
Ineffectiveness of Lactobacillus GG as an
adjunct to lactulose for the treatment of
constipation in children (DBPCR trial)
84
84children
children(2-16
(2-16years)
years)with
withconstipation
constipation
(<3
(<3bowel
bowelmovements
movements/wk)
/wk)>
>12
12weeks
weeks
11 mL/kg/day
mL/kg/day of
of 70%
70% lactulose
lactulose
9
+
+ 10
109 CFU
CFU of
of LGG
LGG +
+ placebo
placebo 2x/day,
2x/day, 12
12
weeks
weeks
nn ::
43
41
43
41
treatment
treatment success
success (>3
(>3 BMs/week
BMs/week with
with no
no fecal
fecal
soiling)
soiling)
at
28/41
31/43
at 12
12 weeks
weeks
28/41 [68%]
[68%]
31/43 [72%]
[72%]
Banaszkiewicz A. J Pediatr 2005;146:364-9.
(p
(p 0.7)
0.7)
Probiotics in GI disease
COMBINATION - INTERACTION
Mechanisms
of action
Clinical
studies
Composition of intestinal
flora
Quality of
the gastrointestinal
health
Thank you